Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan for EGFR-mutated NSCLC with transformed SCLC after platinum resistance
ChiCTR2500113126Phase 2Not yet recruiting
- Sponsor
- Dongguan People's Hospital
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in small cell lung cancer (SCLC), sponsored by Dongguan People's Hospital. Primary endpoint: Objective response rate (ORR). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500113126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113126.